The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.
Diagnosis of alopecia areata
SALT score of less than 50% extension
Has not received any topical or systemic treatment in the last month
Signed informed consent
Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features
Pregnancy or breast-feeding
Patients in medications that could cause hair loss as side-effects
Parallel
Candida Albicans Antigen Injection
Drugsubcutaneous administration of Candida albicans antigen
Treatment response
porcentage of hair growth determined by SALT score
Side effects
Side effects associated to the treatment
Click on the lead sponsor to view all of their trials.
